Sigyn Therapeutics Announces Presentation at Today’s Emerging Growth Conference
January 05, 2022 07:30 ET
|
Sigyn Therapeutics, Inc.
SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (OTC Markets: “SIGY”), a medical technology company focused on the treatment of pathogen-related conditions...
Sigyn Therapeutics CEO Note: 2021 Milestone Achievements / 2022 Clinical Progression / Images of Sigyn Therapy in Action
January 04, 2022 07:30 ET
|
Sigyn Therapeutics, Inc.
SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (OTC Markets: “SIGY”), a medical technology company focused on the treatment of pathogen-related conditions...
Sigyn Therapeutics CEO Note: As Omicron Surges, Consider That the First Authorized COVID-19 Therapies Were Not Drugs or Vaccines
December 17, 2021 08:30 ET
|
Sigyn Therapeutics, Inc.
SAN DIEGO, Dec. 17, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (OTC Markets:“SIGY”), a medical technology company focused on the treatment of pathogen-related conditions...
Sigyn Therapeutics Reports the Successful Completion of a Study to Address Gram-Positive Bacterial Toxins Associated with Sepsis
December 01, 2021 07:30 ET
|
Sigyn Therapeutics, Inc.
In the Past Year, Sigyn Therapy™ Has Been Validated to Address a Broad-Spectrum of Inflammatory Mediators, Gram-Negative Bacterial Toxins, Gram-Positive Bacterial Toxins and Viral Pathogens SAN...
Sigyn Therapeutics Featured on National Public Radio: “Addressing the Cytokine Storm”
August 30, 2021 07:30 ET
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, Aug. 30, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTC Markets: SIGY), a medical technology company focused on the treatment of life-threatening...
Sigyn Therapeutics CEO Note: A Treatment Candidate to Address Bloodstream Pathogens, Deadly Toxins and Inflammatory Disease Targets
August 10, 2021 06:30 ET
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, Aug. 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTC Markets: SIGY), a medical technology company focused on the treatment of sepsis and other...
Sigyn Therapeutics Announces Successful Completion of Animal Pilot Study
July 29, 2021 10:06 ET
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, July 29, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (OTC Markets: SIGY), a medical technology company focused on the treatment of life-threatening...
Sigyn Therapeutics Announces Rapid Elimination of Hepatic Toxins from Human Blood Plasma
July 15, 2021 07:30 ET
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, July 15, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), a medical technology company focused on the treatment of sepsis and other...
Sigyn Therapeutics Reports Preliminary Results of Hepatic Encephalopathy Toxin Study
July 13, 2021 09:31 ET
|
Sigyn Therapeutics, Inc.
SAN DIEGO, July 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), a medical technology company focused on the treatment of sepsis and other...
The Evolution of Blood Purification Technologies to Treat Emerging Pandemic Threats, Including COVID-19
June 28, 2021 09:30 ET
|
Sigyn Therapeutics, Inc.
Webinar Event to Be Held Tomorrow June 29th at 12pm Eastern / 9am Pacific Time SAN DIEGO, CA, June 28, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), a...